7-Nitroindazole protects striatal dopaminergic neurons against MPP +-induced degeneration: An in vivo microdialysis study

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 462-471

  Di Matteo, Vincenzo ^a   Benigno, Arcangelo ^b   Pierucci, Massimo ^a   Giuliano, Davide Antonio ^b   Crescimanno, Giuseppe ^b   Esposito, Ennio ^a   Di Giovanni, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Corpus striatum; in vivo microdialysis; MPP+; Nitric oxide; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 7 NITROINDAZOLE; IODIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; 7-NITROINDAZOLE; DOPAMINE; ENZYME INHIBITOR; INDAZOLE DERIVATIVE; NEURONAL NITRIC OXIDE SYNTHASE; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL LOSS; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; MALE; MICRODIALYSIS; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; REPERFUSION; ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBSTANTIA NIGRA;

RATTUS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; ENZYME INHIBITORS; INDAZOLES; MALE; MICRODIALYSIS; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE I; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 33847768567     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.015     Document Type: Conference Paper

References (41)

1. JELLINGER, K. 1989. Pathology of Parkinson's Disease. In Handbook of Experimental Pharmacology. D.B. Calne, Ed.: Vol. 8: 47-112. Springer, Berlin.
2. SCHERMAN, D. et al. 1989. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26: 551-557.
3. DI GIOVANNI, G. et al. 2007. Biochemical and therapeutic effects of antioxidants in the treatment of Parkinson's disease. In The Basal Ganglia Pathophysiology: Recent Advances. G. Di Giovanni, Ed.: Research Signpost, India. In press.
4. VON BOHLEN UND HALBACH, O., A. SCHOBER & K. KRIEGLSTEIN. 2004. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol. 73: 151-177.
5. JENNER, P. et al. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 32: S82-S87.
6. SIMONIAN, N.A. & J.T. COYLE. 1996. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36: 83-106.
7. MARK, R.J. et al. 1997. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68: 255-264.
8. DEXTER, D.T. et al. 1991. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114: 1953-1975.
9. WATANABE, H. et al. 2004. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur. Neuropsychopharmacol. 14: 93-104.
10. KUROSAKI, R. et al. 2002. Role of nitric oxide synthase against MPTP neurotoxicity in mice. Neurol. Res. 24: 655-662.
11. PRZEDBORSKI, S. et al. 1996. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. 93: 4565-4571.
12. SCHULZ, J.B. et al. 1995. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64: 936-939.
13. BARC, S. et al. 2001. Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors. Neurosci. Lett. 314: 82-86.
14. +. Eur. J. Pharmacol. 126: 345-346.
15. SANTIAGO, M., A. MACHADO & J. CANO. 2001. Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis. J. Neurosci. Methods 108: 181-187.
16. DI MATTEO, V. et al. 2006. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res. 1095: 167-177.
17. DI GIOVANNI, G. et al. 2003. Nitric oxide modulates striatal neuronal activity via soluble guanylyl cyclase: an in vivo microiontophoretic study in rats. Synapse 48: 100-107.
18. GLINKA, Y., M. GASSEN & M.B.H. YOUDIM. 1997. Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural. Transm. 50: 55-66.
19. LOTHARIUS, J., L.L. DUGAN & K.L. O'MALLEY. 1999. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19: 1284-1293.
20. BLUM, D. et al. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65: 135-172.
21. NICKLAS, W.J., I. VYAS & R.E. HEIKKILA. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2,5,6-tetrahydropyridine. Life Sci. 36: 2503-2508.
22. PRZEDBORSKI, S. & M. VILA. 2001. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neurosci. Res. 1: 407-418.
23. HORNYKIEWICZ, O. 1989. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease - a critical analysis of the neurochemical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry 13: 319-328.
24. ZIGMOND, M.J., T.G. HASTINGS & R.G. PEREZ. 2002. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity? Parkinsonism Relat. Disorders 8: 389-393.
25. LANG, A.E. & A.M. LOZANO. 1998. Parkinson's disease: first of two parts. New Engl. J. Med. 339: 1044-1053.
26. AUBIN, N. et al. 1998. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71: 1635-1642.
27. OBATA, T. 1999. Reserpine prevents hydroxyl radical formation by MPP+ in rat striatum. Brain Res. 828: 68-73.
28. MOHANAKUMAR, K.P., D. MURALIKRISHNAN & B. THOMAS. 2000. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced neurotoxicity. Brain Res. 864: 281-290.
29. OBATA, T. & S. KUBOTA. 2001. Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci. Lett. 308: 87-90.
30. TEISMANN, P. & B. FERGER. 2001. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39: 167-174.
31. SAIRAM, K. et al. 2003. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridiniuminduced dopaminergic neurotoxicity in rats. Brain Res. 966: 245-252.
32. MAHARAJ, D.S. et al. 2004. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem. Int. 44: 355-360.
33. MATTHEWS, R.T., L. YANG & M.F. BEAL. 1997. S-methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp. Neurol. 143: 282-286.
34. BECKMAN, J.S. 1991. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J. Dev. Physiol. 15: 53-59.
35. BECKMAN, J.S. et al. 1992. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch. Biochem. Biophys. 198: 438-445.
36. SZABO, C. & V.L. DAWSON. 1998. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. 19: 287-298.
37. KISS, J.P., G. ZSILLA & E.S. VIZI. 2004. Inhibitory effect of nitric oxide on dopamine transporters: interneuronal communication without receptors. Neurochem. Int. 45: 485-489.
38. VOLZ, T.J. & J.O. SCHENK. 2004. L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse 54: 173-182.
39. CASTAGNOLI, K. et al. 1997. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem. Res. Toxicol. 10: 364-368.
40. CHIBA, K., A. TREVOR & N. CASTAGNOLI JR. 1984. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120: 574-578.
41. MARKEY, S.P. et al. 1984. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464-467.